TY  - GEN
N2  - Liquid biopsy provides a minimally-invasive alternative to solid tissue biopsy for assessing tumor-derived molecules such as circulating tumor DNA (ctDNA). Detection and characterization of ctDNA in the blood shows promise in early cancer screening and diagnosis, and has prognostic value for risk-stratification at all stages of disease. ctDNA can also be used for minimally-invasive tumor genotyping, treatment monitoring, and pre-clinical detection of minimal residual disease and recurrence. Although once predicted as a panacea for these applications, the clinical implementation of ctDNA assays has met with significant technical hurdles. Moreover, poorly-understood biological mechanisms and a lack of standardized methods contribute to measurement variability. The work that follows is intended to (1) highlight the need for a deeper understanding of the biological underpinnings of ctDNA release and kinetics, and (2) test the limits of patient-specific and patient-agnostic ctDNA detection technologies in the clinical setting.
DO  - 10.6083/zk51vh59w
DO  - DOI
AB  - Liquid biopsy provides a minimally-invasive alternative to solid tissue biopsy for assessing tumor-derived molecules such as circulating tumor DNA (ctDNA). Detection and characterization of ctDNA in the blood shows promise in early cancer screening and diagnosis, and has prognostic value for risk-stratification at all stages of disease. ctDNA can also be used for minimally-invasive tumor genotyping, treatment monitoring, and pre-clinical detection of minimal residual disease and recurrence. Although once predicted as a panacea for these applications, the clinical implementation of ctDNA assays has met with significant technical hurdles. Moreover, poorly-understood biological mechanisms and a lack of standardized methods contribute to measurement variability. The work that follows is intended to (1) highlight the need for a deeper understanding of the biological underpinnings of ctDNA release and kinetics, and (2) test the limits of patient-specific and patient-agnostic ctDNA detection technologies in the clinical setting.
T1  - Clinical and research applications of circulating tumor DNA detection, monitoring, and dynamics in cancer patients
DA  - 2023
AU  - Boniface, Christopher
L1  - https://digitalcollections.ohsu.edu/record/10077/files/Boniface.Christopher.2023.pdf
PB  - Oregon Health and Science University
PY  - 2023
ID  - 10077
L4  - https://digitalcollections.ohsu.edu/record/10077/files/Boniface.Christopher.2023.pdf
KW  - Genotype
KW  - Circulating Tumor DNA
KW  - Biopsy
KW  - neoplasm
TI  - Clinical and research applications of circulating tumor DNA detection, monitoring, and dynamics in cancer patients
Y1  - 2023
L2  - https://digitalcollections.ohsu.edu/record/10077/files/Boniface.Christopher.2023.pdf
LK  - https://digitalcollections.ohsu.edu/record/10077/files/Boniface.Christopher.2023.pdf
UR  - https://digitalcollections.ohsu.edu/record/10077/files/Boniface.Christopher.2023.pdf
ER  -